Clinical Research Directory

Inclusion Criteria: 1. Female participants aged ≥ 18 years-old 2. Primary diagnosis of migraine according to ICHD-3 3.4 or more migraine days during Observation Period and Screening Visit 4.Migraine attacks present for more than 1 year 5.Rimegepant is prescribed for the preventive treatment of migraine by physician 6.Written informed consent must be obtained before participant is enrolled 7.Not concurrently participating in other interventional clinical studies. Exclusion Criteria: 1. Patients diagnosed with secondary headaches. 2. Women who are pregnant or breastfeeding. 3. Subjects with severe impairments in language, vision, memory, or cognitive function that affect communication and understanding, or those who are unable to complete questionnaires or follow-ups. 4. Subjects lacking the equipment to complete questionnaires on a digital platform. 5. Subjects who are allergic to rimegepant or any of its excipients. 6. Patients with severe liver damage or end-stage renal disease. 7. Patients with a medical history indicating the presence of uncontrolled or unstable cardiovascular disease (such as ischemic heart disease, coronary artery spasm, or cerebral ischemia), or those who have had a myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, cardiac surgery, stroke, or transient ischemic attack within 6 months prior to the screening visit. 8. Any condition deemed by the investigator that might affect the patient's participation in the study.